## Xisong Ke

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9687169/publications.pdf

Version: 2024-02-01

		1040056	1125743	
14	784	9	13	
papers	citations	h-index	g-index	
14	14	14	1213	
all docs	docs citations	times ranked	citing authors	

#	Article	IF	Citations
1	Liquidambaric acid inhibits Wnt $\hat{\mathbb{I}}^2$ -catenin signaling and colon cancer via targeting TNF receptor-associated factor 2. Cell Reports, 2022, 38, 110319.	6.4	20
2	Neddylation is essential for $\hat{l}^2$ -catenin degradation in Wnt signaling pathway. Cell Reports, 2022, 38, 110538.	6.4	11
3	The phytochemical hyperforin triggers thermogenesis in adipose tissue via a Dlat-AMPK signaling axis to curb obesity. Cell Metabolism, 2021, 33, 565-580.e7.	16.2	79
4	Proteomic Exploration of Endocytosis of Framework Nucleic Acids. Small, 2021, 17, e2100837.	10.0	17
5	Tanshinones induce tumor cell apoptosis via directly targeting FHIT. Scientific Reports, 2021, 11, 12217.	3.3	7
6	Oleanolic acid blocks the purine salvage pathway for cancer therapy by inactivating SOD1 and stimulating lysosomal proteolysis. Molecular Therapy - Oncolytics, 2021, 23, 107-123.	4.4	7
7	Small molecule targeting topoisomerase $3\hat{l}^2$ for cancer therapy. Pharmacological Research, 2021, 174, 105927.	7.1	3
8	Small Molecule Palmatine Targeting Musashi-2 in Colorectal Cancer. Frontiers in Pharmacology, 2021, 12, 793449.	3 <b>.</b> 5	12
9	WNT/ $\hat{l}^2$ -Catenin Signaling Pathway Regulating T Cell-Inflammation in the Tumor Microenvironment. Frontiers in Immunology, 2019, 10, 2293.	4.8	165
10	Activating Wnt/ $\hat{l}^2$ -catenin signaling pathway for disease therapy: Challenges and opportunities. , 2019, 196, 79-90.		154
11	Targeting Wnt/ $\hat{l}^2$ -Catenin Signaling for Cancer Immunotherapy. Trends in Pharmacological Sciences, 2018, 39, 648-658.	8.7	159
12	Rapid characterization of chemical constituents and metabolites of Qiâ€Jingâ€Shengâ€Bai granule by using UHPLC–Qâ€TOFâ€MS. Journal of Separation Science, 2018, 41, 1960-1972.	2.5	15
13	Is Î <sup>2</sup> -Catenin a Druggable Target for Cancer Therapy?. Trends in Biochemical Sciences, 2018, 43, 623-634.	7.5	101
14	Bruceine D inhibits hepatocellular carcinoma growth by targeting $\hat{l}^2$ -catenin/jagged1 pathways. Cancer Letters, 2017, 403, 195-205.	7.2	34